Transcriptome analysis reveals the clinical significance of CXCL13 in Pan-Gyn tumors
-
Published:2024-03-09
Issue:3
Volume:150
Page:
-
ISSN:1432-1335
-
Container-title:Journal of Cancer Research and Clinical Oncology
-
language:en
-
Short-container-title:J Cancer Res Clin Oncol
Author:
Ding Yue,Zhou Quan,Ding Bo,Zhang Yang,Shen Yang
Abstract
Abstract
Background
Gynecologic and breast tumors (Pan-Gyn) exhibit similar characteristics, and the role of CXCL13 in anti-tumor immunity and it’s potential as a biomarker for immune checkpoint blockade (ICB) therapy have been gradually revealed. However, the precise role of CXCL13 in Pan-Gyn remains unclear, lacking a systematic analysis.
Methods
We analyzed 2497 Pan-Gyn samples from the TCGA database, categorizing them into high and low CXCL13 expression groups. Validation was conducted using tumor expression datasets sourced from the GEO database. Correlation between CXCL13 and tumor immune microenvironment (TIME) was evaluated using multiple algorithms. Finally, we established nomograms for 3-year and 5-year mortality.
Results
High expression of CXCL13 in Pan-Gyn correlates with a favorable clinical prognosis, increased immune cell infiltration, and reduced intra-tumor heterogeneity. Model was assessed using the C-index [BRCA: 0.763 (0.732–0.794), UCEC: 0.821 (0.793–0.849), CESC: 0.736 (0.684–0.788), and OV: 0.728 (0.707–0.749)], showing decent prediction of discrimination and calibration.
Conclusion
Overall, this study provides comprehensive insights into the commonalities and differences of CXCL13 in Pan-Gyn, potentially opening new avenues for personalized treatment.
Funder
Beijing Xisike Clinical Oncology Research Foundation
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R (2018) A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33(4):690–705. https://doi.org/10.1016/j.ccell.2018.03.014 2. Cannistra SA, Pujade-Lauraine E (2019) Progress and promise in treating gynecologic cancers. J Clin Oncol 37(27):2383–2385. https://doi.org/10.1200/JCO.19.01097 3. Chung SH, Woldenberg N, Roth AR, Masamed R, Conlon W, Cohen JG, Joines MM, Patel MK (2020) BRCA and beyond: comprehensive image-rich review of hereditary breast and gynecologic cancer syndromes. Radiographics 40(2):306–325. https://doi.org/10.1148/rg.2020190084 4. Cosgrove J, Novkovic M, Albrecht S, Pikor NB, Zhou Z, Onder L, Morbe U, Cupovic J, Miller H, Alden K, Thuery A, O’Toole P, Pinter R, Jarrett S, Taylor E, Venetz D, Heller M, Uguccioni M, Legler DF, Lacey CJ, Coatesworth A, Polak WG, Cupedo T, Manoury B, Thelen M, Stein JV, Wolf M, Leake MC, Timmis J, Ludewig B, Coles MC (2020) B cell zone reticular cell microenvironments shape CXCL13 gradient formation. Nat Commun 11(1):3677. https://doi.org/10.1038/s41467-020-17135-2 5. Harris BS, Bishop KC, Kuller JA, Ford AC, Muasher LC, Cantrell SE, Price TM (2020) Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause 27(2):243–248. https://doi.org/10.1097/GME.0000000000001447
|
|